Tremor and Other Hyperkinetic Movements (Aug 2012)

Methodological Issues in Clinical Drug Development for Essential Tremor

  • Michael A. Carranza,
  • Madeline R. Snyder,
  • Rodger J. Elble,
  • Angelique E. Boutzoukas,
  • Theresa A. Zesiewicz

DOI
https://doi.org/10.7916/D8P55M7F
Journal volume & issue
Vol. 2

Abstract

Read online

Essential tremor (ET) is one of the most common tremor disorders in the world. Despite this, only two medications have received Level A recommendations from the American Academy of Neurology to treat it (primidone and propranolol). Even though these medications provide relief to a large group of ET patients, up to 50% of patients are non-responders. Additional medications to treat ET are needed. This review discusses some of the methodological issues that should be addressed for quality clinical drug development in ET.